Background
Methods
Study population
Data source
Statistical methods
Results
Baseline clinical characteristics
Characteristics | PKT group (n = 5) | HD group (n = 104) | PD group (n = 98) | p-value |
---|---|---|---|---|
Age(years) | 36.2 ± 10.1 | 42.4 ± 9.7 | 39.5 ± 11.6 | 0.053 |
Male, n (%) | 4(80.0) | 65(62.5) | 56(57.1) | 0.437 |
BMI (kg/m2) | 22.1(20.2,26.1) | 21.2(18.9,23.6) | 21.5(19.9,23.8) | 0.470 |
Blood group (A:B:AB:O) | 2:2:0:1 | 27:26:13:38 | 27:29:8:34 | 0.706 |
Duration on dialysis (months) | 0(0,0) | 15.5(6.0,36.0) | 24.0(6.0,36.0) | 0.583 |
Hospital stay (days) | 17.0(12.5,19.5) | 20.0(15.0,26.0) | 18.5(15.0,29.0) | 0.337 |
Follow-up time (months) | 19.0(10.5,35.0) | 12.5(3.0,22.0) | 12.0(6.0,20.0) | 0.961 |
Preoperative medical condition, n (%) | ||||
Diabetes mellitus | 0(0) | 13(12.5) | 6(6.1) | 0.121 |
Cardiovascular disease | 0(0) | 5(4.8) | 2(2.0) | 0.490 |
Hypertension | 5(100) | 91(87.5) | 90(91.8) | 0.313 |
Antihypertensive agents, n (%) | 5(100) | 76(73.1) | 75(76.5) | 0.572 |
HBV (+) | 0(0) | 9(8.7) | 8(8.2) | 0.900 |
Cause of end-stage renal disease, n (%) | 0.188 | |||
Glomerulonephritis | 4(80) | 68(64.8) | 64(66.0) | |
Diabetes | 0(0) | 5(4.8) | 1(1.0) | |
Hypertensive nephrosclerosis | 0(0) | 2(1.9) | 1(1.0) | |
Polycystic kidney disease | 1(20) | 6(5.7) | 1(1.0) | |
Chronic pyelonephritis | 0(0) | 1(1.0) | 2(2.1) | |
Others | 0(0) | 2(1.9) | 6(6.2) | |
Unknown | 0(0) | 21(20.0) | 22(22.7) | |
Pretransplant urinary volume (ml/24 h) | 2000(1750,2000) | 200(100,500) | 500(100,1000) | 0.073 |
Anuric patients (%) | 0(0) | 19(18.3) | 18(18.4) | 0.986 |
Immunosuppresion therapy, n (%) | 0.310 | |||
St + FK + MMF | 5(100) | 97(93.3) | 95(96.9) | |
St + CyA | 0(0) | 2(1.9) | 0(0) | |
St + CyA + MMF | 0(0) | 5(4.8) | 3(3.1) |
Laboratory Parameters | PKT group (n = 5) | HD group (n = 104) | PD group (n = 98) | p-value |
---|---|---|---|---|
Serum white blood cell (109/L) | 6.2 ± 1.4 | 7.1 ± 1.8 | 7.1 ± 2.0 | 0.832 |
Neut % | 62.6 ± 8.2 | 68.1 ± 7.4 | 68.8 ± 8.6 | 0.539 |
Lymph% | 21.6(19.6,31.0) | 21.6(17.4,26.2) | 20.5(15.8,26.0) | 0.168 |
Haemoglobin (g/L) | 101.4 ± 8.9 | 115.8 ± 19.8 | 105.1 ± 18.7 | < 0.001* |
Serum potassium (mmol/L) | 3.5(2.9,4.3) | 4.3(3.9,4.8) | 3.8(3.3,4.3) | < 0.001* |
Serum sodium (mmol/L) | 140.0(137.5142.0) | 139.0(138.0,141.0) | 139.0(136.0,141.0) | 0.213 |
PTH (pg/ml) | 202.4(149.7707.4) | 221.0(87.8431.2) | 216.3(134.1469.0) | 0.198 |
Serum calcium (mmol/L) | 2.1 ± 0.2 | 2.4 ± 0.2 | 2.3 ± 0.2 | 0.008* |
Serum phosphate (mmol/L) | 1.8(1.7,3.0) | 1.7(1.3,2.3) | 1.8(1.3,2.3) | 0.864 |
Serum creatinine (umol/L) | 751.0(706.5785.3) | 827.2(647.0,1068.0) | 1104.1(827.8,1426.7) | < 0.001* |
Serum urea nitrogen (mmol/L) | 36.1 ± 13.7 | 18.7 ± 6.6 | 21.9 ± 6.4 | 0.001* |
Serum uric acid (μmol/L) | 533.0(372.5642.0) | 346.0(290.3424.5) | 408.5(384.8462.5) | < 0.001* |
Serum albumin (g/L) | 48.9 ± 4.2 | 48.4 ± 4.4 | 42.7 ± 4.3 | < 0.001* |
ALT(U/L) | 14.0(7.0,19.4) | 14.0(9.7,20.0) | 16.0(11.0,20.5) | 0.151 |
Blood Glucose (mmol/L) | 4.5(3.3,5.9) | 4.4(3.8,4.9) | 4.3(3.6,5.0) | 0.983 |
Cholesterol (mmol/L) | 4.3 ± 0.9 | 4.8 ± 1.1 | 5.1 ± 1.2 | 0.086 |
Triglyceride (mmol/L) | 1.8(1.2,3.7) | 1.6(1.1,2.9) | 1.7(1.2,2.6) | 0.683 |
LDL (mmol/L) | 2.1(2.0,2.8) | 2.5(2.2,3.1) | 2.9(2.2,3.6) | 0.057 |
HDL (mmol/L) | 1.0(0.9,1.2) | 1.1(0.9,1.6) | 1.1(0.9,1.4) | 0.675 |
Lymphocyte subtypes(%) | ||||
CD3+(%) | 76.3(70.2,84.2) | 70.8(62.9, 76.6) | 71.0(66.0, 75.9) | 0.868 |
CD4+/CD8+ | 1.7(1.2,1.9) | 1.6(1.2, 2.1) | 1.6(1.2, 2.0) | 0.766 |
CD19+(%) | 6.8(5.5,11.0) | 11.1(7.7, 13.6) | 9.5(7.2, 13.8) | 0.636 |
CD16+CD56+(%) | 13.1(6.8,18.2) | 14.6(9.9, 19.2) | 5.6(10.1, 19.5) | 0.742 |
Characteristics | Donated to PKT (n = 5) | Donated to HD (n = 79) | Donated to PD (n = 83) | p-value |
---|---|---|---|---|
Age(years) | 42.8 ± 17.0 | 40.3 ± 13.7 | 37.7 ± 16.5 | 0.451 |
Male, n (%) | 5(100.0) | 52(65.8) | 62(74.7) | 0.216 |
BMI (kg/m2) | 21.8(20.4,26.5) | 21.5(19.5,23.0) | 21.2(19.8,24.0) | 0.972 |
Blood group (A:B:AB:O) | 2:2:0:1 | 13:20:9:37 | 18:23:11:31 | 0.649 |
Hypertension(%) | 2(40.0) | 36(41.8) | 25(34.4) | 0.355 |
ICU stay | 2.0(1.5,21.0) | 2.0(1.5,4.0) | 2.0(1.0,4.5) | 0.510 |
HLA mismatching | 0.098 | |||
0–2 | 3(60.0) | 23(29.1) | 13(15.7) | |
3–4 | 1(20.0) | 8(10.1) | 13(15.7) | |
5–6 | 1(20.0) | 48(60.8) | 57(68.7) | |
Serum white blood cell (109/L) | 12.7 ± 9.0 | 12.2 ± 5.7 | 14.6 ± 9.9 | 0.424 |
Serum creatinine (umol/L) | 64.1(36.5,65.5) | 67.5(48.7107.3) | 74.0(48.0,95.0) | 0.947 |
Cholesterol (mmol/L) | 3.3 ± 1.1 | 3.2 ± 1.3 | 3.7 ± 1.6 | 0.429 |
Triglyceride (mmol/L) | 1.2 ± 0.6 | 1.4 ± 0.7 | 1.3 ± 0.8 | 0.830 |
eGFR(mL/min/1.73m2) | 110.0(98.0,133.0) | 129.4(72.1215.2) | 109.5(72.8209.0) | 0.930 |
Cause of death,n (%) | 0.179 | |||
Cerebrovascular accident | 2(40.0) | 27(34.6) | 28(37.3) | |
Trauma | 3(60.0) | 23(29.5) | 26(34.7) | |
Cerebral tumor | 0(0) | 3(3.8) | 2(2.7) | |
Others | 0(0) | 3(3.8) | 8(10.7) | |
Unknown | 0(0) | 22(28.2) | 11(14.7) |
Post-transplant renal function outcomes
Characteristics | PKT group (n = 5) | HD group (n = 104) | PD group (n = 98) | P-value |
---|---|---|---|---|
Haemoglobin after transplantation at different time (g/L) | ||||
1 month | 115.6 ± 14.6 | 108.0 ± 20.1 | 103.7 ± 22.8 | 0.210 |
6 months | 129.4 ± 10.1 | 125.3 ± 21.7 | 133.5 ± 20.8 | 0.059 |
The last follow-up | 135.0 ± 17.8 | 125.2 ± 28.9 | 126.2 ± 26.6 | 0.817 |
Serum albumin after transplantation at different time (g/L) | ||||
1 month | 46.5 ± 2.0 | 42.3 ± 4.4 | 41.6 ± 5.3 | 0.394 |
6 months | 46.9 ± 2.0 | 44.9 ± 3.4 | 45.3 ± 4.0 | 0.537 |
The last follow-up | 46.1 ± 3.3 | 43.6 ± 5.2 | 43.6 ± 5.6 | 0.951 |
Cholesterol after transplantation at different time (mmol/L) | ||||
1 month | 4.9 ± 1.1 | 4.9 ± 1.4 | 4.8 ± 1.1 | 0.477 |
6 months | 4.4 ± 0.5 | 4.8 ± 0.9 | 5.2 ± 0.9 | 0.064 |
The last follow-up | 4.0 ± 0.8 | 4.8 ± 1.1 | 4.9 ± 1.0 | 0.655 |
Triglyceride after transplantation at different time (mmol/L) | ||||
1 month | 2.3(1.1,4.4) | 1.8(1.5,2.6) | 2.0(1.5,2.8) | 0.533 |
6 months | 1.5(1.1,3.0) | 1.6(1.2,2.1) | 2.1(1.8,2.5) | 0.010* |
The last follow-up | 1.1(1.0,2.8) | 1.6(1.1,2.3) | 1.9(1.2,2.5) | 0.106 |
Serum calcium after transplantation at different time (mmol/L) | ||||
1 month | 2.4(2.3,2.5) | 2.3(2.2,2.4) | 2.3(2.3,2.4) | 0.374 |
6 months | 2.4(2.2,2.7) | 2.5(2.3,2.6) | 2.4(2.4,2.7) | 0.950 |
The last follow-up | 2.4(2.2,2.5) | 2.5(2.3,2.5) | 2.4(2.3,2.6) | 0.899 |
Serum phosphate after transplantation at different time (mmol/L) | ||||
1 month | 0.7(0.4,0.9) | 0.6(0.5,0.8) | 0.7(0.5,0.9) | 0.291 |
6 months | 0.9(0.9,1.2) | 1.0(0.8,1.1) | 0.9(0.8,1.1) | 0.138 |
The last follow-up | 0.9(0.9,1.1) | 1.0(0.8,1.1) | 0.9(0.8,1.1) | 0.079 |
eGFR after transplantation at different time (mL/min/1.73m2) | ||||
1 month | 63.1 ± 13.8 | 68.5 ± 23.7 | 68.0 ± 28.7 | 0.902 |
6 month | 58.0 ± 8.7 | 68.5 ± 23.2 | 74.9 ± 22.9 | 0.167 |
The last follow-up | 57.0 ± 10.3 | 69.7 ± 24.7 | 68.5 ± 26.0 | 0.737 |
Other laboratory parameters post transplantation
Post-transplant complications
Complications | PKT group (n = 5) | HD group (n = 104) | PD group (n = 98) | P-value |
---|---|---|---|---|
Delayed recovery of graft function, n (%) | 0(0) | 19(18.3) | 16(16.3) | 0.715 |
Acute rejection, n (%) | 0(0) | 7(6.7) | 6(6.1) | 0.860 |
Surgical complications, n (%) | ||||
Urinaryfistula | 0(0) | 1(1.0) | 1(1.0) | 1.000 |
Hydronephrosis | 0(0) | 6(5.8) | 4(4.1) | 0.820 |
Hematoma | 0(0) | 4(3.8) | 4(4.1) | 1.000 |
Infection, n (%) | ||||
Cytomegalovirus | 0(0) | 21(20.2) | 20(20.4) | 0.970 |
JC virus | 0(0) | 13(12.5) | 13(13.3) | 0.871 |
BK virus | 0(0) | 17(16.3) | 15(15.3) | 0.840 |
Varicella zoster virus | 0(0) | 0(0) | 1(1.0) | 0.485 |
Fungal infectio | 0(0) | 4(3.8) | 5(5.1) | 0.927 |
Tuberculosis | 0(0) | 2(1.9) | 0(0) | 0.498 |
Urinary tract infection | 1(20.0) | 7(6.7) | 11(11.2) | 0.263 |
Acute bacterial pneumonia | 1(20.0) | 17(16.3) | 12(12.2) | 0.406 |
Patient mortality and graft failure
Characteristics | PKT group (n = 5) | HD group (n = 104) | PD group (n = 98) | p-value |
---|---|---|---|---|
Transplatation outcomes, %(n) | ||||
Patient survival | 100.0(5/5) | 96.2(100/104) | 96.9(95/98) | 1.000 |
Graft survival | 100.0(5/5) | 93.3(97/104) | 93.9(92/98) | 0.860 |
Death-censored graft survival | 100.0(5/5) | 97.1(101/104) | 96.9(95/98) | 1.000 |
Causes of graft failure, % (n) | < 0.001* | |||
Acute rejection | 0(0/0) | 0(0/7) | 28.6(2/7) | |
Severe infection | 0(0/0) | 28.6(2/7) | 57.1(4/7) | |
Primary failure | 0(0/0) | 0(0/7) | 14.3(1/7) | |
Surgical complications | 0(0/0) | 57.1(4/7) | 0(0/7) | |
Others | 0(0/0) | 14.3(1/7) | 0(0/7) |
Univariate analysis | Multivariate analysis | |||||
---|---|---|---|---|---|---|
P | RR | 95% CI | P | RR | 95% CI | |
Graft failure in HD | ||||||
Younger recipient age | 0.731 | 0.99 | 0.92–1.06 | 0.947 | ||
Male (vs female) | 0.100 | 0.25 | 0.05–1.30 | 0.290 | ||
Smaller BMI | 0.761 | 1.02 | 0.89–1.17 | |||
Shorter dialysis duration | 0.211 | 0.96 | 0.91–1.02 | 0.250 | ||
DGF | 0.017 | 6.23 | 1.40–27.85 | 0.588 | ||
Surgical complications | < 0.001 | 26.12 | 5.70–119.80 | < 0.001 | 26.12 | 5.70–119.80 |
Acute rejection | 0.629 | 0.044 | – | |||
Infection | 0.472 | 0.55 | 0.11–2.83 | |||
Graft failure in PD | ||||||
Younger recipient age | 0.071 | 1.06 | 0.99–1.15 | 0.105 | ||
Male (vs female) | 0.084 | 0.15 | 0.02–1.29 | 0.112 | ||
Smaller BMI | 0.420 | 0.88 | 0.64–1.20 | |||
Shorter dialysis duration | 0.373 | 1.01 | 0.99–1.04 | 0.962 | ||
DGF | 0.010 | 9.39 | 1.72–51.29 | 0.010 | 9.39 | 1.72–51.29 |
Surgical complications | 0.700 | 0.05 | – | 0.708 | ||
Acute rejection | 0.036 | 6.15 | 1.12–33.67 | |||
Infection | 0.058 | 7.96 | 0.93–68.11 |